Our current pipeline
We are on the cutting edge of uro-oncology and specialty cancers with the development of our investigational product candidates, which we believe have the potential to upend the status quo and open up new avenues to treat patients.
Uro-oncology
UGN-102
Recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)
Nonclinical
Phase 1
Phase 2
Phase 3
PDUFA
Unmet need
Bladder cancers are described as muscle invasive or non-muscle invasive based on whether they have invaded into the muscular layer of the wall of the bladder. Of the approximately 60,000 newly diagnosed cases of non-muscle invasive bladder cancer (NMIBC) per year, 54% are considered low grade (LG). While there is a low risk of progression and mortality in this population, chronically relapsing disease remains a pervasive problem. In patients who recur, it is estimated that 68% will experience 2 or more recurrence episodes throughout the course of their disease.
The current standard of care for treating patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is a surgical procedure known as transurethral resection of bladder tumor (TURBT). Due to a lack of treatment options to reduce recurrences in these patients, they are typically managed with repeated TURBT for each subsequent recurrence. Repeated TURBT procedures can impact patients’ physical health and quality of life and are even associated with an increased risk in mortality. Due to the high disease recurrence rates, LG-IR-NMIBC patients will likely need multiple TURBTs over the course of their lifetime, leaving them more prone to these surgical burdens.
There are currently no drugs approved by the U.S. FDA for the treatment of recurrent LG-IR-NMIBC. If approved, UGN-102 will become the first medicine for this patient population.
About
UroGen® is developing UGN-102 (mitomycin) for intravesical solution for tumor ablation and as an alternative to repetitive TURBT. UGN-102 is an investigational formulation that utilizes UroGen’s innovative technology, RTGel® reverse-thermal hydrogel.
Status
UroGen announced positive topline results from the ATLAS and ENVISION Phase 3 clinical trials. The FDA is currently reviewing the new drug application (NDA) for UGN-102 for the treatment of adults with recurrent LG-IR-NMIBC.
Uro-oncology
UGN-103
Recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)
Nonclinical
Phase 1
Phase 2
Phase 3
PDUFA
Unmet need
Bladder cancers are described as muscle invasive or non-muscle invasive based on whether they have invaded into the muscular layer of the wall of the bladder. Of the approximately 60,000 newly diagnosed cases of non-muscle invasive bladder cancer (NMIBC) per year, 54% are considered low grade (LG). While there is a low risk of progression and mortality in this population, chronically relapsing disease remains a pervasive problem. In patients who recur, it is estimated that 68% will experience 2 or more recurrence episodes throughout the course of their disease.
The current standard of care for treating patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is a surgical procedure known as transurethral resection of bladder tumor (TURBT). Due to a lack of treatment options to reduce recurrences in these patients, they are typically managed with repeated TURBT for each subsequent recurrence. Repeated TURBT procedures can impact patients’ physical health and quality of life and are even associated with an increased risk in mortality. Due to the high disease recurrence rates, LG-IR-NMIBC patients will likely need multiple TURBTs over the course of their lifetime, leaving them more prone to these surgical burdens.
There are currently no drugs approved by the U.S. FDA for the treatment of recurrent LG-IR-NMIBC. If approved, UGN-102 will become the first medicine for this patient population.
About
UroGen entered into a license and supply agreement with medac GmbH to develop next-generation products by combining our proprietary RTGel® technology with medac’s proprietary formulation of mitomycin. This includes UGN-103, which combines UroGen’s RTGel® technology with medac’s licensed mitomycin formulation. If approved, anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten the manufacturing process and simplify the reconstitution procedure. The agreement and development program potentially allows UroGen to extend the patent protection on its urothelial cancer franchise. Medac’s intellectual property protection for its mitomycin formulation is expected to last until June 2035, and UroGen has pending U.S. patent applications that may provide protection until December 2041.
Status
Enrollment continues in the Phase 3 UTOPIA trial evaluating UGN-103, our next-generation product for recurrent LG-IR-NMIBC. UTOPIA is a single-arm, multicenter study with a protocol similar to the ENVISION trial. We expect to complete enrollment this year and anticipate reporting top-line data in 2026.
Uro-oncology
UGN-104
Low-grade upper tract urothelial cancer (LG-UTUC)
Nonclinical
Phase 1
Phase 2
Phase 3
PDUFA
Unmet need
Patients with low-grade upper tract urothelial cancer (LG-UTUC) are typically treated with kidney-sparing management, which includes endoscopic resection with or without intracavitary drug therapy. Kidney-sparing endoscopic surgery for small, solitary, low-grade tumors reduces the morbidity associated with radical surgery, without compromising oncological outcomes. However, endoscopic therapy is associated with high rates of local disease recurrence of about 50%-90% and requires lifelong surveillance, which can be associated with treatment-related complications such as ureteral stricture, perforation of the upper tract, bleeding, and infection. There remains a need for innovative and effective kidney-sparing approaches to LG-UTUC that avoid surgery, in turn reducing the likelihood of disease recurrence and improving patient outcomes. Over the past decade, research investigating the use of intravesical immunotherapy and chemotherapy agents for UTUC treatment has been challenged by the difficulty of achieving adequate dwell time, due to continuous urine production and drug dilution. This highlights a clinical need for an agent that conforms to the complex anatomy of the upper tract and demonstrates sufficient efficacy as well as durability of response for the treatment of LG-UTUC, either as adjuvant or primary therapy.
About
UroGen entered into a license and supply agreement with medac GmbH to develop next-generation products by combining our proprietary RTGel® technology with medac’s proprietary formulation of mitomycin. This includes UGN-104, which combines UroGen’s RTGel® technology with medac’s licensed mitomycin formulation. The agreement and development program potentially allows UroGen to extend the patent protection on its urothelial cancer franchise. Medac’s intellectual property protection for its mitomycin formulation is expected to last until June 2035, and UroGen has pending U.S. patent applications that may provide protection until December 2041.
Status
UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-104 in LG-UTUC in the first half of 2025.
immuno-Uro-oncology
UGN-301
(Anti-CTLA-4)
High-grade non-muscle invasive bladder cancer (HG-NMIBC)
Nonclinical
Phase 1
Phase 2
Phase 3
PDUFA
Unmet need
Bladder cancers are described as muscle invasive or non-muscle invasive (NMIBC) based on whether they have invaded into the muscular layer of the wall of the bladder. Of the approximately 60,000 newly diagnosed cases of NMIBC per year, high grade (HG) NMIBC represents approximately 30% of all NMIBC. Standard treatment for HG-NMIBC is transurethral resection of bladder tumors followed by adjuvant intravesical immunotherapy with Bacillus Calmette-Guérin (BCG). Unfortunately, a third of patients will not respond to BCG, and half of patients who initially respond to BCG will experience recurrence or progression. Radical cystectomy is strongly advocated in patients who are BCG‑refractory or relapse following BCG treatment due to the risk of invasive and metastatic disease, highlighting the need for nonsurgical treatment options in the setting of BCG failure.
Significant advances in the field of immunotherapy have found that immune checkpoint inhibitors like anti-CTLA-4 can harness the body’s natural immune defenses to combat cancer. When administered systemically, anti-CTLA-4 therapy has led to improved outcomes in patients suffering from advanced cancers. However, experience in a variety of advanced cancers has shown there are significant risks to immunotherapies administered systemically, including side effects that range from mild to potentially life-threatening. Such dose-limiting toxicity is currently preventing patients from benefiting from the full therapeutic potential of this promising agent.
About
UGN-301 is our in-licensed, anti-CTLA-4 monoclonal antibody (zalifrelimab), prepared with reverse-thermal hydrogel for intravesical administration into the bladder. Intravesical administration of UGN-301 is designed to increase drug concentrations in the bladder without significant systemic exposure, potentially diminishing the systemic toxicity associated with CTLA-4 blockade.
UroGen is evaluating UGN-301, our in-licensed anti-CTLA-4 antibody (zalifrelimab), as a monotherapy and as combination therapy for the intravesical treatment of HG-NMIBC.
Status
UroGen is evaluating UGN-301, in a multi-arm Phase 1 study of UGN-301 as monotherapy and in combination with other agents.
immuno-Uro-oncology
UGN-301 + UGN-201
(TLR 7 agonist)
High-grade non-muscle invasive bladder cancer (HG-NMIBC)
Nonclinical
Phase 1
Phase 2
Phase 3
PDUFA
Unmet need
Bladder cancers are described as muscle invasive or non-muscle invasive (NMIBC) based on whether they have invaded into the muscular layer of the wall of the bladder. Of the approximately 60,000 newly diagnosed cases of NMIBC per year, high grade (HG) NMIBC represents approximately 30% of all NMIBC. Standard treatment for HG-NMIBC is transurethral resection of bladder tumors followed by adjuvant intravesical immunotherapy with Bacillus Calmette-Guérin (BCG). Unfortunately, a third of patients will not respond to BCG, and half of patients who initially respond to BCG will experience recurrence or progression. Radical cystectomy is strongly advocated in patients who are BCG‑refractory or relapse following BCG treatment due to the risk of invasive and metastatic disease, highlighting the need for nonsurgical treatment options in the setting of BCG failure.
About
UGN-301 is UroGen’s in-licensed anti-CTLA-4 monoclonal antibody (zalifrelimab). UGN-201 is our proprietary formulation of imiquimod, a toll-like receptor 7 (TLR 7) agonist.
When combined, we believe the combination may stimulate both innate and adaptive immune responses, both of which are important for fully harnessing the power of the immune system to fight cancer. We believe that this combination makes local immunotherapy a potentially more effective treatment option while minimizing systemic exposure and potential side effects.
Status
UroGen is evaluating UGN-301 in combination with UGN-201 in a multi-arm Phase 1 study. Safety and dosing data from this combination arm are expected in 2025.
immuno-Uro-oncology
UGN-301 + gemcitabine
High-grade non-muscle invasive bladder cancer (HG-NMIBC)
Nonclinical
Phase 1
Phase 2
Phase 3
PDUFA
Unmet need
Bladder cancers are described as muscle invasive or non-muscle invasive (NMIBC) based on whether they have invaded into the muscular layer of the wall of the bladder. Of the approximately 60,000 newly diagnosed cases of NMIBC per year, high grade (HG) NMIBC represents approximately 30% of all NMIBC. Standard treatment for HG-NMIBC is transurethral resection of bladder tumors followed by adjuvant intravesical immunotherapy with Bacillus Calmette-Guérin (BCG). Unfortunately, a third of patients will not respond to BCG, and half of patients who initially respond to BCG will experience recurrence or progression. Radical cystectomy is strongly advocated in patients who are BCG‑refractory or relapse following BCG treatment due to the risk of invasive and metastatic disease, highlighting the need for nonsurgical treatment options in the setting of BCG failure.
About
UGN-301 is UroGen’s in-licensed anti-CTLA-4 monoclonal antibody (zalifrelimab). Gemcitabine is a chemotherapy that is used intravesically to treat high-grade NMIBC where it is administered as a liquid formulation.
When combined, we believe the combination may stimulate both innate and adaptive immune responses, both of which are important for fully harnessing the power of the immune system to fight cancer. We believe that this combination makes local immunotherapy a potentially more effective treatment option while minimizing systemic exposure and potential side effects.
Status
UroGen is evaluating UGN-301 in combination with gemcitabine in a multi-arm Phase 1 study. Safety and dosing data from this combination arm are expected in 2025.
immuno-Uro-oncology
UGN-501
(ICVB-1042 Investigational next-gen oncolytic virus)
High-grade non-muscle invasive bladder cancer (HG-NMIBC)
Nonclinical
Phase 1
Phase 2
Phase 3
PDUFA
Unmet need
Bladder cancers are described as muscle invasive or non-muscle invasive (NMIBC) based on whether they have invaded into the muscular layer of the wall of the bladder. Of the approximately 60,000 newly diagnosed cases of NMIBC per year, high grade (HG) NMIBC represents approximately 30% of all NMIBC. Standard treatment for HG-NMIBC is transurethral resection of bladder tumors followed by adjuvant intravesical immunotherapy with Bacillus Calmette-Guérin (BCG). Unfortunately, a third of patients will not respond to BCG, and half of patients who initially respond to BCG will experience recurrence or progression. Radical cystectomy is strongly advocated in patients who are BCG refractory or relapse following BCG treatment due to the risk of invasive and metastatic disease, highlighting the need for nonsurgical treatment options in the setting of BCG failure.
About
In February 2025, UroGen acquired ICVB-1042 (now known as UGN-501) a next-generation oncolytic virus. This addition meaningfully enhances UroGen’s pipeline by introducing a highly innovative approach to selectively targeting and destroying cancer cells while simultaneously activating a robust anti-tumor immune response. ICVB-1042 was thoughtfully engineered to achieve efficient cell entry, strong selectivity for malignant cells, and rapid replication within the tumor microenvironment—features that drive both direct tumor cell lysis and the induction of a durable, tumor-specific immune response.
Status
Our development plan for UGN-501 is advancing, with IND-enabling studies expected to begin in 2025. We intend to evaluate several modes of administration, including delivery using our proprietary RTGel® technology. While the initial focus will be on bladder cancer, UroGen will explore UGN-501’s potential to address a broader range of malignancies beyond the genitourinary space.
Active
Completed
Planned
UGN-102, UGN-103, UGN-104, UGN-301, UGN-201, and UGN-501 are investigational drugs in development. The safety and efficacy of these agents have not been established by any regulatory body including the FDA.